The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells

International Journal of Oncology

Volumn 37, Issue 1, 2010, Pages 187-193

  Patsos, Helena A ^a   Greenhough, Alexander ^a   Hicks, Diane J ^a   Kharusi, Manal A L ^a   Collard, Tracey J ^a   Lane, Jon D ^a   Paraskeva, Christos ^a   Williams, Ann C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Arachidonoylethanolamide (anandamide, AEA); Cannabinoid; Colorectal carcinoma; Cyclooxygenase 2; Non apoptotic cell death

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; FLUOROURACIL; INDOMETACIN; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; SULINDAC; AMIDE; ARACHIDONIC ACID DERIVATIVE; BAX PROTEIN, HUMAN; CANNABINOID RECEPTOR AFFECTING AGENT; CYCLOOXYGENASE 2 INHIBITOR; ENDOCANNABINOID; PTGS2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL DESTRUCTION; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM MUCOSA; RNA INTERFERENCE; SENSITIZATION; CARCINOMA; COLON TUMOR; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; ARACHIDONIC ACIDS; BCL-2-ASSOCIATED X PROTEIN; CANNABINOID RECEPTOR MODULATORS; CARCINOMA; CELL DEATH; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ENDOCANNABINOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HT29 CELLS; HUMANS; POLYUNSATURATED ALKAMIDES; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 77953211523     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000666     Document Type: Article

References (49)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Roth W and Reed JC: Apoptosis and cancer: when BAX is TRAILing away. Nat Med 8: 216-218, 2002. (Pubitemid 34250094)
3. Sinicrope FA and Penington RC: Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther 4: 1475-1483, 2005.
4. Violette S, Poulain L, Dussaulx E, et al: Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98: 498-504, 2002. (Pubitemid 34208549)
5. Guzman M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3: 745-755, 2003.
6. Bifulco M, Laezza C, Pisanti S and Gazzerro P: Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148: 123-135, 2006. (Pubitemid 43873031)
7. Sarfaraz S, Adhami VM, Syed DN, Afaq F and Mukhtar H: Cannabinoids for cancer treatment: progress and promise. Cancer Res 68: 339-342, 2008. (Pubitemid 351380057)
8. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564, 1990.
9. Munro S, Thomas KL and Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65, 1993.
10. Howlett AC, Qualy JM and Khachatrian LL: Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29: 307-313, 1986.
11. Davis MI, Ronesi J and Lovinger DM: A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 278: 48973-48980, 2003.
12. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML and Guzman M: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64: 5617-5623, 2004.
13. Greenhough A, Patsos HA, Williams AC and Paraskeva C: The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 121: 2172-2180, 2007.
14. Wang D, Wang H, Ning W, Backlund MG, Dey SK and DuBois RN: Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68: 6468-6476, 2008.
15. Devane WA, Hanus L, Breuer A, et al: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949, 1992.
16. Di Marzo V, Bifulco M and De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771-784, 2004.
17. Ligresti A, Bisogno T, Matias I, et al: Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677-687, 2003.
18. Laezza C, Pisanti S, Crescenzi E and Bifulco M: Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 580: 6076-6082, 2006.
19. Joseph J, Niggemann B, Zaenker KS and Entschladen F: Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53: 723-728, 2004.
20. Ramer R and Hinz B: Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst 100: 59-69, 2008.
21. Grimaldi C, Pisanti S, Laezza C, et al: Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312: 363-373, 2006.
22. Maccarrone M, Lorenzon T, Bari M, Melino G and Finazzi-Agro A: Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J Biol Chem 275: 31938-31945, 2000.
23. Patsos HA, Hicks DJ, Dobson RR, et al: The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 54: 1741-1750, 2005.
24. Siegmund SV, Uchinami H, Osawa Y, Brenner DA and Schwabe RF: Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 41: 1085-1095, 2005.
25. Contassot E, Wilmotte R, Tenan M, et al: Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol 63: 956-963, 2004.
26. Izzo AA, Aviello G, Petrosino S, et al: Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 86: 89-98, 2008.
27. Ueda N: Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat 68-69: 521-534, 2002.
28. Kozak KR, Crews BC, Morrow JD, et al: Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44877-44885, 2002.
29. Elder DJ, Baker JA, Banu NA, Moorghen M and Paraskeva C: Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 198: 428-434, 2002.
30. LeBlanc H, Lawrence D, Varfolomeev E, et al: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281, 2002.
31. Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science 290: 989-992, 2000.
32. Kaidi A, Williams AC and Paraskeva C: Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 9: 210-217, 2007. (Pubitemid 46420864)
33. Diaz GD, Paraskeva C, Thomas MG, Binderup L and Hague A: Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60: 2304-2312, 2000. (Pubitemid 30225198)
34. Wei MC, Zong WX, Cheng EH, et al: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
35. Wang S and El-Deiry WS: TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628-8633, 2003.
36. Ibrahim MM, Porreca F, Lai J, et al: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3093-3098, 2005.
37. Brown JM and Wilson G: Apoptosis genes and resistance to cancer therapy: what does the experimental and clinical data tell us? Cancer Biol Ther 2: 477-490, 2003.
38. Klionsky DJ: Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 8: 931-937, 2007.
39. Kroemer G and Levine B: Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 9: 1004-1010, 2008.
40. Sperandio S, de Belle I and Bredesen DE: An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 97: 14376-14381, 2000.
41. Wang Y, Li X, Wang L, et al: An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci 117: 1525-1532, 2004. (Pubitemid 38559827)
42. Kroemer G, Galluzzi L, Vandenabeele P, et al: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 16: 3-11, 2009.
43. Galluzzi L, Maiuri MC, Vitale I, et al: Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14: 1237-1243, 2007. (Pubitemid 46969863)
44. Van Dross RT: Metabolism of anandamide by COX-2 is necessary for endocannabinoid induced cell death in tumorigenic keratinocytes. Mol Carcinogenesis 48: 724-732, 2009.
45. De Petrocellis L, Melck D, Palmisano A, et al: The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 95: 8375-8380, 1998.
46. Bifulco M, Laezza C, Portella G, et al: Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 15: 2745-2747, 2001.
47. Ramer R, Brune K, Pahl A and Hinz B: R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. Biochem Biophys Res Commun 286: 1144-1152, 2001. (Pubitemid 32924889)
48. Oliver L, Cordel S, Barbieux I, et al: Resistance to apoptosis is increased during metastatic dissemination of colon cancer. Clin Exp Metastasis 19: 175-180, 2002. (Pubitemid 34264088)
49. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J and Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91: 894-899, 2001. (Pubitemid 32178662)